Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109270 | 0.90 | RAB9A (0.39) | MEN1KMT2AKDM4ERAB9AALDH1A1 | |
| SCHEMBL20109323 | 0.90 | RAB9A (0.39) | MEN1KMT2AKDM4ERAB9AALDH1A1 | |
| SCHEMBL20109326 | 0.88 | RAB9A (0.38) | MEN1KMT2AKDM4ERAB9AALDH1A1 | |
| SCHEMBL20109325 | 0.88 | RAB9A (0.38) | MEN1KMT2AKDM4ERAB9AALDH1A1 | |
| SCHEMBL20113529 | 0.87 | MEN1 (0.45) | MEN1KMT2AKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL20113906 | 0.87 | MEN1 (0.45) | MEN1KMT2AKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL20109328 | 0.86 | NPC1 (0.37) | MEN1KMT2AKDM4ERAB9AALDH1A1 | |
| SCHEMBL20109329 | 0.86 | HPGD (0.37) | MEN1KMT2AKDM4ERAB9AALDH1A1 | |
| SCHEMBL20109133 | 0.83 | TSHR (0.40) | MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL17596725 | 0.81 | GAA (0.40) | MEN1KMT2AALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633403-B2 | N-heterocyclic phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | NANP, PPIP5K2, PHPT1 | MEN1 469/4885KMT2A 2508/4885KDM4E 3603/4885 |
| US-10633403-B2 | N-heterocyclic phosphines | NANP, PPIP5K2, PHPT1 | MEN1 469/4885KMT2A 2508/4885KDM4E 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.